

November 15, 2021

To: SHC and LPCH Medical Staff

From: Stanford Health Care Clinical Laboratories

Dear Stanford Clinicians,

Stanford Molecular Pathology Laboratory launched T-cell Receptor Gene Rearrangement Minimal/measurable Residual Disease (TCRMRD) Assessment by next-generation sequencing for patients with T-cell malignancies. This assay enables tracking of malignant T-cell clonotypes previously detected by T-cell Receptor Gene Rearrangement Diagnostic Assessment (TCRDX). New emerging dominant clonotypes can be identified by this MRD assay and tracked prospectively and retrospectively in other MRD specimens. The test requirements are as follows:

1. A diagnostic specimen previously tested positive at Stanford is required for subsequent tracking of malignant T-cell clonotype. The malignant clonotype is quantified and tracked in a clinical report stored in EPIC
2. Specimen types: only peripheral blood and bone marrow aspirates are currently accepted.
3. EPIC order codes: TCRMRD-B for peripheral blood and TCRMRD-BM for bone marrow aspirate specimens.
4. Turnaround time: 1-2 weeks

For patients with no previous diagnostic testing performed at Stanford, TCRMRD may be ordered but a diagnostic specimen for TCRDX MUST be provided for MRD tracking. Please contact the laboratory at 650-723-6574 for any inquiries.

Thank you so much for your partnership in improving the standard of care for our patient population.

Order information can be found below:

<https://stanfordlab.com/content/stanfordlab/en/test-details/t/TCRMRD.html>



Px Code	Name	Type	Resulting Agencies
LABTCRMRD-B	TCRMRD (aka T-Cell Receptor Gene Rearrangement Measurable/Minimal Residual Disease Assessment by Next-Generation Sequencing, Blood)	Lab	SHC
LABTCRMRD-BM	TCRMRD (aka T-Cell Receptor Gene Rearrangement Measurable/Minimal Residual Disease Assessment by Next-Generation Sequencing, Bone Marrow)	Lab	SHC

James L. Zehnder, MD
Professor of Pathology and Medicine (Hematology)
Director of Clinical Pathology, Department of Pathology
Stanford University School of Medicine
Director, Coagulation and Molecular Genetic Pathology Laboratories
Stanford Health Care